These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 32163632)

  • 21. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.
    Blom DJ; Harada-Shiba M; Rubba P; Gaudet D; Kastelein JJP; Charng MJ; Pordy R; Donahue S; Ali S; Dong Y; Khilla N; Banerjee P; Baccara-Dinet M; Rosenson RS
    J Am Coll Cardiol; 2020 Jul; 76(2):131-142. PubMed ID: 32646561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey.
    D'Erasmo L; Gallo A; Cefalù AB; Di Costanzo A; Saheb S; Giammanco A; Averna M; Buonaiuto A; Iannuzzo G; Fortunato G; Puja A; Montalcini T; Pavanello C; Calabresi L; Vigna GB; Bucci M; Bonomo K; Nota F; Sampietro T; Sbrana F; Suppressa P; Sabbà C; Fimiani F; Cesaro A; Calabrò P; Palmisano S; D'Addato S; Pisciotta L; Bertolini S; Bittar R; Kalmykova O; Béliard S; Carrié A; Arca M; Bruckert E
    Orphanet J Rare Dis; 2021 Sep; 16(1):381. PubMed ID: 34496902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
    Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis.
    Stefanutti C; Morozzi C; Di Giacomo S; Sovrano B; Mesce D; Grossi A
    J Clin Lipidol; 2016; 10(4):782-789. PubMed ID: 27578108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing the challenging homozygous familial hypercholesterolemia patient: Academic insights and practical approaches for a severe dyslipidemia, a National Lipid Association Masters Summit.
    Hovingh GK; Goldberg AC; Moriarty PM
    J Clin Lipidol; 2017; 11(3):602-616. PubMed ID: 28506384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry.
    Alonso R; Díaz-Díaz JL; Arrieta F; Fuentes-Jiménez F; de Andrés R; Saenz P; Ariceta G; Vidal-Pardo JI; Almagro F; Argueso R; Prieto-Matos P; Miramontes JP; Pintó X; Rodriguez-Urrego J; Perez de Isla L; Mata P
    J Clin Lipidol; 2016; 10(4):953-961. PubMed ID: 27578128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations.
    Stein EA; Dann EJ; Wiegman A; Skovby F; Gaudet D; Sokal E; Charng MJ; Mohamed M; Luirink I; Raichlen JS; Sundén M; Carlsson SC; Raal FJ; Kastelein JJP
    J Am Coll Cardiol; 2017 Aug; 70(9):1162-1170. PubMed ID: 28838366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
    Vishwanath R; Hemphill LC
    J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene.
    Al-Hinai AT; Al-Abri A; Al-Dhuhli H; Al-Waili K; Al-Sabti H; Al-Yaarubi S; Al-Hashmi K; Banerjee Y; Al-Zakwani I; Al-Rasadi K
    Angiology; 2013 May; 64(4):287-92. PubMed ID: 23162007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management and clinical outcomes of patients with homozygous familial hypercholesteremia in Saudi Arabia.
    Kholaif N; Mohamed TI; Alharbi IS; Aljenedil SA; AlHumaidan H; Al-Ashwal A; Almahfouz A; Algorashi S; Almasood A; Baqal OJ
    Monaldi Arch Chest Dis; 2023 Feb; 93(4):. PubMed ID: 36786168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment.
    Raal FJ; Santos RD
    Atherosclerosis; 2012 Aug; 223(2):262-8. PubMed ID: 22398274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study.
    Stefanutti C; Pang J; Di Giacomo S; Wu X; Wang X; Morozzi C; Watts GF; Lin J
    J Clin Lipidol; 2019; 13(4):608-617. PubMed ID: 31255589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.
    Ito MK; Watts GF
    Drugs; 2015 Oct; 75(15):1715-24. PubMed ID: 26370207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study.
    Raal FJ; Sjouke B; Hovingh GK; Isaac BF
    Atherosclerosis; 2016 May; 248():238-44. PubMed ID: 27017151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia.
    Græsdal A; Bogsrud MP; Holven KB; Nenseter MS; Narverud I; Langslet G; Brekke M; Retterstøl K; Arnesen KE; Ose L
    J Clin Lipidol; 2012; 6(4):331-9. PubMed ID: 22836070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia.
    Zwiener RJ; Uauy R; Petruska ML; Huet BA
    J Pediatr; 1995 May; 126(5 Pt 1):728-35. PubMed ID: 7751996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives.
    Sanna C; Stéphenne X; Revencu N; Smets F; Sassolas A; Di Filippo M; Descamps OS; Sokal EM
    Atherosclerosis; 2016 Apr; 247():97-104. PubMed ID: 26894473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.
    Bruckert E; Kalmykova O; Bittar R; Carreau V; Béliard S; Saheb S; Rosenbaum D; Bonnefont-Rousselot D; Thomas D; Emery C; Khoshnood B; Carrié A
    Atherosclerosis; 2017 Feb; 257():130-137. PubMed ID: 28131047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disease control via intensified lipoprotein apheresis in three siblings with familial hypercholesterolemia.
    Taylan C; Schlune A; Meissner T; Ažukaitis K; Udink Ten Cate FE; Weber LT
    J Clin Lipidol; 2016; 10(6):1303-1310. PubMed ID: 27919346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study).
    Schettler VJ; Muellendorff F; Schettler E; Platzer C; Norkauer S; Julius U; Neumann CL
    Ther Apher Dial; 2019 Oct; 23(5):467-473. PubMed ID: 30663261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.